The Longer-Term Benefits and Harms of Glucagon-Like Peptide-1 Receptor Agonists: a Systematic Review and Meta-Analysis
Jason T. Alexander, Erin M. Staab, Wen Wan, Melissa I. Franco, Alexandra Knitter, M. Reza Skandari, Shari Bolen, Nisa M. Maruthur, Elbert S. Huang, Louis H. Philipson, Aaron N. Winn, Celeste C. Thomas, Meltem Zeytinoglu, Valerie G. Press, Elizabeth L. Tung, Kathryn E. Gunter, Brittany Bindon, Sanjay Jumani, Neda Laiteerapong
Topics & Concepts
MedicineMeta-analysisTerm (time)Glucagon-like peptide-1Glucagon-like peptide 1 receptorMEDLINESystematic reviewInternal medicineReceptorEndocrinologyAgonistDiabetes mellitusType 2 diabetesBiochemistryPhysicsChemistryQuantum mechanicsDiabetes Treatment and ManagementHyperglycemia and glycemic control in critically ill and hospitalized patientsBariatric Surgery and Outcomes